Experts hailed exciting news for some people with sickle cell disease in England as the health watchdog decided to grant access to gene-editing therapy on the NHS.

The UK’s Medicines and Healthcare Regulatory Agency (MHRA) approved Casgevy for sickle cell disease in 2023, followed by ...

The innovative treatment exa-cel had previously been approved for treating beta-thalassemia in the UK ... the most promising gene therapies for sickle cell disease is exa-cel, which uses the ...

A £1.65 million treatment has been approved for use for some NHS patients, offering some with an inherited blood disorder ...

for beta-thalassemia and sickle cell disease. Although it's a long way from the market, the drug could be one of the first to use the revolutionary CRISPR/Cas9 gene editing technology to correct a ...

Doudna spoke about all the new opportunities created by the development of the gene-editing tool CRISPR-Cas9. In March last year, Nice rejected Casgevy for people with severe sickle cell disease.

The CRISPR-based gene therapy Casgevy (exagamglogene autotemcel) has been made available to patients with sickle cell disease in England, following positive guidance issued by the National ...

Stanford researchers introduced affordable gene-editing kits ready for the classroom, aiming to make the field more accessible for high school students.